한글목차

본 보고서는 주요 7개국(미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본)의 천식 치료제 ARNUITY ELLIPTA의 동향을 조사했으며, 치료제 개요, 작용기전, 임상개발 데이터, 관련 법규, 시판 및 개발 중인 약품과의 경쟁 분석, 국가별 국가별 시장 규모 추정 및 예측, SWOT 분석, 애널리스트의 견해 등을 정리하여 전해드립니다.

보고서 하이라이트:

• 천식 시장 시나리오는 광범위한 연구와 의료비 지출 증가로 인해 향후 몇 년 동안 변화할 것으로 예상됩니다.
• 각 회사는 질병을 치료 및 개선하고, 과제를 평가하고, ARNUITY ELLIPTA의 우위에 영향을 미칠 수 있는 기회를 얻기 위해 새로운 접근 방식에 초점을 맞춘 치료제를 개발하고 있습니다.
• 다른 천식 신약들이 아르니티엘립타와 치열한 시장 경쟁을 벌일 것으로 예상되며, 조만간 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.
• 법 규제 마일스톤과 개발 활동에 대한 자세한 설명을 통해 천식 분야에서 ARNUITY ELLIPTA의 현재 개발 시나리오를 제공합니다.
• 2027년부터 2032년까지 아루니티 엘립타의 예측 판매 데이터를 상세히 분석하여 천식 분야에서 아루니티 엘립타의 전체 시나리오를 파악하고, 치료제 포트폴리오에 대한 의사결정 과정을 지원합니다.

목차

제1장 보고서 소개

제2장 천식의 ARNUITY ELLIPTA : 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료제)

제4장 경쟁 구도(후기 단계 신흥 치료제)

제5장 ARNUITY ELLIPTA : 시장 평가

• 천식의 ARNUITY ELLIPTA : 시장 전망
• 주요 7개국 분석
  • 천식 치료제 ARNUITY ELLIPTA 시장 규모
• 국가별 시장 분석
  • 시장 규모 : 미국
  • 시장 규모 : 독일
  • 시장 규모 : 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"ARNUITY ELLIPTA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ARNUITY ELLIPTA for Asthma in the seven major markets. A detailed picture of the ARNUITY ELLIPTA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ARNUITY ELLIPTA for Asthma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARNUITY ELLIPTA market forecast analysis for Asthma in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary:

ARNUITY ELLIPTA (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma. Arnuity Ellipta is not indicated for the relief of acute bronchospasm. It reduces inflammation and helps prevent and control asthma symptoms.

• Dosage and administration

ARNUITY ELLIPTA should be administered only by the orally inhaled route. After inhalation, the patient should rinse their mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis. If symptoms arise between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief.

ARNUITY ELLIPTA should be administered as one inhalation once daily by the orally inhaled route. ARNUITY ELLIPTA should be used at the same time every day. Do not use ARNUITY ELLIPTA >1 time every 24 h.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ARNUITY ELLIPTA description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on ARNUITY ELLIPTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARNUITY ELLIPTA research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ARNUITY ELLIPTA.
• The report contains forecasted sales of ARNUITY ELLIPTA for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for ARNUITY ELLIPTA in Asthma.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARNUITY ELLIPTA Analytical Perspective by DelveInsight

• In-depth ARNUITY ELLIPTA Market Assessment

This report provides a detailed market assessment of ARNUITY ELLIPTA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ARNUITY ELLIPTA Clinical Assessment

The report provides the clinical trials information of ARNUITY ELLIPTA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARNUITY ELLIPTA dominance.
• Other emerging products for Asthma are expected to give tough market competition to ARNUITY ELLIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARNUITY ELLIPTA in Asthma.
• Our in-depth analysis of the forecasted sales data of ARNUITY ELLIPTA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARNUITY ELLIPTA in Asthma.

Key Questions:

• What is the product type, route of administration and mechanism of action of ARNUITY ELLIPTA?
• What is the clinical trial status of the study related to ARNUITY ELLIPTA in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARNUITY ELLIPTA development?
• What are the key designations that have been granted to ARNUITY ELLIPTA for Asthma?
• What is the forecasted market scenario of ARNUITY ELLIPTA for Asthma?
• What are the forecasted sales of ARNUITY ELLIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARNUITY ELLIPTA for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

Table of Contents

1. Report Introduction

2. ARNUITY ELLIPTA Overview in Asthma

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ARNUITY ELLIPTA Market Assessment

• 5.1. Market Outlook of ARNUITY ELLIPTA in Asthma
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ARNUITY ELLIPTA in the 7MM for Asthma
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ARNUITY ELLIPTA in the United States for Asthma
  • 5.3.2. Market Size of ARNUITY ELLIPTA in Germany for Asthma
  • 5.3.3. Market Size of ARNUITY ELLIPTA in France for Asthma
  • 5.3.4. Market Size of ARNUITY ELLIPTA in Italy for Asthma
  • 5.3.5. Market Size of ARNUITY ELLIPTA in Spain for Asthma
  • 5.3.6. Market Size of ARNUITY ELLIPTA in the United Kingdom for Asthma
  • 5.3.7. Market Size of ARNUITY ELLIPTA in Japan for Asthma

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options